Process Technology. Regardless of anything to the contrary, all processes, recipes, and manufacturing, fabrication, assembly and test techniques, and related improvements (“process technology”) provided and/or developed by or on behalf of Seller or Manufacturer shall be wholly owned by and the property of Seller and Manufacturer, and Seller and Manufacturer shall not be limited or restricted by this Agreement with respect to any process technology unless clearly stated to the contrary in a writing signed by an Officer of Manufacturer identifying the specific information in precise detail.
Process Technology. In no event may Conexant or any Conexant Affiliate sublicense any Licensed Patent or Transferred Know-How to any third party for the purpose of enabling such third party to provide semiconductor fabrication services (or similar services) to anyone other than Conexant or Conexant Affiliates.
Process Technology. ABX shall own all ABX Process Technology; provided, however, that, on and after the designation of a Candidate Drug that binds to and is directed against a Collaboration Antigen, AZ shall own, and ABX and its Affiliates shall assign to AZ, the Manufacturing Data and any cell lines, including research and master cell banks, expressing Candidate Drugs, Licensed Products or other Antibodies that bind to and are directed against such Collaboration Antigen. Subject to the process development and manufacturing and supply commitments set forth in this Article 7 and in the Process Science/Clinical Manufacture Agreement and the Manufacturing and Supply Agreement, ABX and its Affiliates shall grant to AZ a [Confidential treatment requested] worldwide, right and license (with the right to grant sublicenses through multiple tiers of sublicensees subject to the last sentence of this Section 7.9) under the ABX Process Patent Rights and ABX Process Know-How Rights to Exploit Antibodies, Candidate Drugs and Licensed Products for which ABX is performing activities under the Process Science/Clinical Manufacture Agreement for use in the Commercial Field. From and after the date that ABX ceases to perform process development or manufacturing and supply activities with respect to an Antibody, a Candidate Drug or a Licensed Product under the Process Science/Clinical Manufacture Agreement and the Manufacturing and Supply Agreement, ABX and its Affiliates shall grant to AZ the exclusive, worldwide, [Confidential treatment requested] right and license (with the right to grant sublicenses through multiple tiers of sublicensees subject to the last sentence of this Section 7.9) under the ABX Process Patent Rights and ABX Process Know-How Rights to Exploit such Antibody, Candidate Drug and Licensed Product for use in the Commercial Field. Notwithstanding anything to the contrary in this Agreement, the right of AZ to grant sublicenses under the ABX Process Patent Rights and ABX Process Know-How Rights applicable to an Antibody, Candidate Drug or Licensed Product shall be limited solely to the extent Reasonably Necessary to manufacture and supply such Antibody, Candidate Drug or Licensed Product for use in the Commercial Field (and related process development and testing activities).
Process Technology. Subject to the license grants to AZ under this Agreement, as between the Parties, ABX shall own and retain all right, title and interest in and to all of the ABX Process Technology (together with all Patent Rights and other intellectual property rights therein). AZ shall own and retain all right, title and interest in and to all of the AZ Process Technology (together with all Patent Rights and other intellectual property rights therein).
Process Technology. Spansion desires to have SMIC manufacture the Contract Wafers at the Facilities using certain Spansion Process Technology, provided the Facilities meet Spansion’s specifications. To this end, the Parties shall execute from time to time during the term individual Process Supplements substantially in the form set forth in Exhibit A1 for each Spansion Process (e.g., for a particular process node) to be implemented at the Facilities. The initial Process Supplement will be provided by Spansion within fifteen (15) days after execution of this Foundry Agreement and attached hereto as Exhibit A1.
Process Technology. A. MAGI shall solely own any Research Service Invention that (1) constitutes Process Technology that is not an Improvement and (2) is Predominantly Funded by MAGI (as that term is defined below) (the "MAGI Research Service Process Technology Inventions"), and any such Process Technology shall be deemed to be MAGI New Process Technology. In the event that one or more employees of Millennium is an inventor of a MAGI Research Service Process Technology Invention, Millennium shall cause such employee(s) to assign all of his/her rights in such invention to, including all intellectual property rights therein, to Millennium and, thereafter, Millennium shall assign all such rights to MAGI or Monsanto (as directed in writing by Monsanto). "